Knight Therapeutics Inc. announced that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 CAD | -0.81% | +3.04% | +17.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.53% | 455M | |
+15.72% | 78.37B | |
+11.98% | 9.08B | |
-12.85% | 5.06B | |
+54.35% | 4.85B | |
+15.44% | 2.37B | |
-20.85% | 2.36B | |
+24.62% | 2.27B | |
-29.25% | 2.22B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO